Hi There!

*Thanks for reading!*

We’re currently looking to hire an additional PCDC Project Manager. Please share the position details with your network of contacts.

**New paper linking genomic data with PCDC clinical data**

A new publication in the *Journal of Clinical Oncology* demonstrates the value of linking genomic data with PCDC clinical data to study the prognostic strength of T cell-inflamed gene expression and neoantigen load in high-risk neuroblastoma.

**Pilot launch of clinical trials matching tool**

As part of The Leukemia & Lymphoma Society (LLS) PedAL Initiative, the PCDC team has developed a tool to rapidly and accurately match children with relapsed acute myeloid leukemia to targeted treatments in North America. GEARBOx (Genomic Eligibility Algorithm at Relapse for Better Outcomes) is a web-based tool that uses a matching algorithm to identify potentially appropriate clinical trials based on COG eligibility criteria. The first full HIBiSCus Executive Committee meeting was held in September, with SJCRH nearly ready for signature. We will help support the PCDC’s continued expansion of GEARBOx as we work to forward to incorporating user feedback and adding data from additional disease groups in preparation for a wider launch.

**Announcements**

**Our director Sam Volchenboum discussed his vision for the future of pediatric oncology in an interview and blog post.**

**Our team has grown! Here we are at our September strategy meeting.**

**We are grateful to our advisory board members and the outside group of clinical, data science, and digital health experts who will provide strategic and operational guidance for the PCDC, while each consortium will focus on a specific disease group.**

**Please join us at 11am CT for the first event in our new quarterly series of thought leadership talks hosted by the PCDC.**

**We look forward to working together to transform pediatric cancer care for children and families!**

**Get involved!**

We are looking for members to broaden our thinking and challenge our norms, so please feel free to reach out with your suggestions and requests.

---

**Drug Compendium**

*Please note: The Drug Compendium is provided as a resource and does not necessarily reflect the PCDC's endorsement or recommendation of any specific drug.*

<table>
<thead>
<tr>
<th>Disease</th>
<th>Drug</th>
<th>Approved by Food and Drug Administration (FDA)</th>
<th>Approved by European Medicines Agency (EMA)</th>
<th>Approved by other regulatory agencies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuroblastoma (INRG)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia (ALL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphoma (Hodgkin)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinoblastoma (Global REACH)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone Tumors (HIBiSCus)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone Tumors (HIBiSCus)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
---

**Sign Up for Updates**

Stay up to date with the latest news and updates from the PCDC by signing up for our newsletter. We also welcome input, feedback, and new ideas as we work towards our common goal of improving pediatric cancer care for children and families around the world.

---

**Contact Us**

Pediatric Cancer Data Commons, 5454 S. Shore Drive, Chicago, IL 60615

email the INRG Strategy Development Committee

---

**Managing Preferences**

Manage preferences

---

**Unsubscribe**

Unsubscribe

---

**Thank you!**

We hope you found this information useful. Please feel free to reach out with any questions or comments.